OGD2 Pharma
Biotherapy developer targeting the tumour-restricted OAcGD2 antigen for high-risk neuroblastoma treatment
Highlights
- New on EvolcAdded 2026-11-02
About OGD2 Pharma
OGD2 Pharma develops antibody-based biotherapies that target O-acetylated GD2 (OAcGD2), a tumour-restricted antigen. Its lead programme, OGD201, is a humanised monoclonal antibody for high-risk neuroblastoma, and the pipeline also includes a licensed CAR-T programme, an antibody-drug conjugate and a biomarker diagnostic in preclinical or early development.
The company is a privately held biotechnology business and a venture of Remora Biotech. It states that it is seeking strategic partners and co-investors to advance OGD201 and is also offering partnership opportunities in ADCs, multispecific antibodies and CAR-based cell therapies.
OGD2 Pharma is headquartered in Nantes, France, and was founded in 2014 as a carve-out of ATLAB Pharma, a previous Remora Biotech venture. OGD201 has received Rare Pediatric Disease Designation from the FDA, and the company received a Bpifrance ADD Deeptech grant to advance it.
Product: OAcGD2-targeting antibody therapies for neuroblastoma and other solid tumours, with a pipeline including ADC, CAR-T and biomarker programmes.
Jobs at OGD2 Pharma
More biotech & pharma companies
Oncodesign Services
Preclinical CRO running in vivo pharmacology, imaging and radiopharmaceutical studies for biotech and pharma sponsorsNew on EvolcRemote-friendlyOne Biosciences
Single-cell tumour profiling from biopsy samples for oncologists and pharma and biotech drug developersNew on EvolcOrakl Oncology
Oncology drug discovery and clinical-response prediction for biopharma companies and research hospitalsYoung companyNew on EvolcOrganotechnie
Manufactures peptones, protein hydrolysates and magnesium pidolate for pharmaceutical, biotechnology and industrial fermentation customersNew on EvolcOsivax
Develops universal vaccines for influenza and other infectious diseases using an oligoDOM nanoparticle platformNew on EvolcPanpharma
Develops, manufactures and distributes injectable medicines for healthcare establishments in more than 100 countriesNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- ElementorHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Google reCAPTCHAHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- ApacheHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.